• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4839885)   Today's Articles (10960)
For: Dubois V, Nieder M, Collot F, Negrouk A, Nguyen TT, Gangwar S, Reitz B, Wattiez R, Dasnois L, Trouet A. Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin. Eur J Cancer 2006;42:3049-56. [PMID: 16644202 DOI: 10.1016/j.ejca.2005.10.030] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2005] [Revised: 10/24/2005] [Accepted: 10/24/2005] [Indexed: 11/26/2022]
Number Cited by Other Article(s)
1
Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity – are we about to clear this hurdle? Eur J Cancer 2023;185:94-104. [PMID: 36966697 DOI: 10.1016/j.ejca.2023.02.019] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 02/19/2023] [Accepted: 02/21/2023] [Indexed: 02/26/2023]
2
Casazza A, Van Helleputte L, Van Renterghem B, Pokreisz P, De Geest N, De Petrini M, Janssens T, Pellens M, Diricx M, Riera-Domingo C, Wozniak A, Mazzone M, Schöffski P, Defert O, Reyns G, Kindt N. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Mol Cancer Ther 2022;21:568-581. [PMID: 35149549 PMCID: PMC9377749 DOI: 10.1158/1535-7163.mct-21-0518] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 11/13/2021] [Accepted: 02/08/2022] [Indexed: 01/07/2023]
3
Jiang J, Shen N, Ci T, Tang Z, Gu Z, Li G, Chen X. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2019;31:e1904278. [PMID: 31549774 DOI: 10.1002/adma.201904278] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Revised: 08/27/2019] [Indexed: 06/10/2023]
4
Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. Eur J Cancer 2017;86:240-247. [PMID: 29055839 DOI: 10.1016/j.ejca.2017.09.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 09/14/2017] [Indexed: 10/18/2022]
5
Cornillie J, Wozniak A, Pokreisz P, Casazza A, Vreys L, Wellens J, Vanleeuw U, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P. In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Mol Cancer Ther 2017;16:1566-1575. [DOI: 10.1158/1535-7163.mct-16-0832] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 04/20/2017] [Accepted: 05/15/2017] [Indexed: 11/16/2022]
6
Qi L, Li SH, Si LB, Lu M, Tian H. Expression of THOP1 and its relationship to prognosis in non-small cell lung cancer. PLoS One 2014;9:e106665. [PMID: 25180910 PMCID: PMC4152321 DOI: 10.1371/journal.pone.0106665] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/30/2014] [Indexed: 11/19/2022]  Open
7
Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Am J Cancer Res 2012;2:156-78. [PMID: 22400063 PMCID: PMC3296471 DOI: 10.7150/thno.4068] [Citation(s) in RCA: 190] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Accepted: 01/28/2012] [Indexed: 12/11/2022]  Open
8
Law B, Tung CH. Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and Imaging. Bioconjug Chem 2009;20:1683-95. [DOI: 10.1021/bc800500a] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
9
Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, Rochaix P, Nicolazzi C, Ribes F, Mazerolles C, Assouly E, Vialatte K, Hor I, Kearsey J, Trouet A. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res 2008;14:1258-65. [PMID: 18281561 DOI: 10.1158/1078-0432.ccr-07-1165] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
10
Florent JC, Monneret C. Doxorubicin Conjugates for Selective Delivery to Tumors. Top Curr Chem (Cham) 2007;283:99-140. [DOI: 10.1007/128_2007_12] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA